ArticleTherapeutic advances in respiratory disease
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis.Allergy · 2025Pooled it
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Effectiveness and Safety of Budesonide/Formoterol in Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Article
- BetaFrontiers in medicine · 2026Review
- A qualitative interview study to investigate opportunities for improvement in routine asthma care using a clinical decision support system.Scientific reports · 2025Article
- Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe.BMJ open respiratory research · 2025Article
- Carbon emissions from the increasing use of inhaled corticosteroid-LABA medications: a primary care used case from Singapore.NPJ primary care respiratory medicine · 2025Article
- Guideline-driven and dependable management of asthma: an evidence-based systematic review.Annals of medicine and surgery (2012) · 2025Article
- Evaluation of Medication Errors among Inpatients in a Tertiary Government Hospital's Pulmonary Medicine Service: A Cross-sectional Retrospective Study.Acta medica Philippina · 2025Article
- The Association Between Short-Acting βAdvances in therapy · 2024Observational
- SABAs as Reliever Medications in Asthma Management: Evidence-Based Science.Advances in therapy · 2023Article
- Short-acting βERJ open research · 2023Article
- Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risks of overusing short-acting β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.